Improved Complete Response in the Patients Injected with Atezolizumab

Release Date: 26-Nov-2020

Combination therapy when injected in the patients suffering from stage 2 or 3 triple -negative breast cancer observed improved complete response. The combination drug that was used in the clinical research study was: neoadjuvant atezolizumab (Tecentriq) to nab-paclitaxel (Abraxane) plus doxorubicin and cyclophosphamide. The group of the enrolled patients that received the combination drug received pathological complete response rate 57.6% as well as the placebo group only received pathological complete response rate of 41.1%. Independent of the PD-L1 status, the combination of the drug showed acceptable safety profile, therefore the whole treatment regimen was classified as a curative treatment for millions of patients.

An old study was focused towards adding the drug atezolizumab to nab-paclitaxel which further led to the conclusion that it led to improved progression free survival as well as overall survival rate in the enrolled patients having PD-L1 positive metastatic TNBC. Whereas, the recent study led to the conclusion that the combination benefited the enrolled patients regardless of their PD-L1 status. 333 patients were enrolled in the respective study. In the patients having positive PD-L1 status received 68.8% pathologic complete response. The patients enrolled in the respective clinical trial who received atezolizumab-chemotherapy regimen, pathological complete response was found to be 47.7% when compared with the placebo group who were observed to had 34.4% pathological complete response.

Therefore, it was concluded that that the combination improved the overall event free survival as well as overall survival rate in the patients. Some of the common side effects that were observed in the enrolled patients were: nausea, diarrhea, alopecia and headache. According to the researchers involved in the respective study, the combination will be responsible for providing benefits to the cancer patients across the globe, once it will get approved by the regulatory body.